Osman Khawar
Internal Medicine · Escondido, CANPI 1598813644
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $902 of the $1,019 with a category attached, or 88.5%. It is spread thinly across 16 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $449 and has fallen 99.6% since, to $2 in 2025.
Across 50 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$194
- Otsuka America Pharmaceutical, Inc.$173
- Mallinckrodt Enterprises LLC$144
- Akebia Therapeutics Inc$85
- Fresenius USA Marketing, Inc.$78
- Amgen$48
- plus $297 from 10 others
Across 322 payments — averaging $3671.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$434K
- GSK$404K
- Akebia Therapeutics Inc$279K
- Merck$33K
- AstraZeneca$15K
- Vertex$13K
- plus $3K from 1 others
What the payments were for
- Travel & lodging$202%
- Food & beverage$90288%
- Education$9710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $194 |
| Otsuka America Pharmaceutical, Inc. | 4 | $173 |
| Mallinckrodt Enterprises LLC | 4 | $144 |
| Akebia Therapeutics Inc | 5 | $85 |
| Fresenius USA Marketing, Inc. | 4 | $78 |
| Amgen(2 entities) | 3 | $48 |
| GSK | 3 | $46 |
| Vifor Pharma, Inc. | 2 | $40 |
| Nxstage Medical, Inc. | 2 | $39 |
| OPKO Pharmaceuticals, LLC | 2 | $35 |
| Bayer | 1 | $27 |
| Bard Peripheral Vascular, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
| Travere Therapeutics, Inc. | 6 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$113
How this compares
$1,019 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 69 | $69,129 |
| VelphoroSucroferric Oxyhydroxide | 16 | $41,672 |
| FarxigaDapagliflozin Propanediol | 22 | $32,590 |
| VeltassaPatiromer Calcium Sorbitex | 20 | $26,446 |
| JanuviaSitagliptin Phosphate | 25 | $24,547 |
| OzempicSemaglutide | 18 | $22,057 |
| EliquisApixaban | 19 | $19,095 |
| Sevelamer Carbonate | 31 | $13,197 |
| ProsolParenteral Amino Acid 20% No.1 | 48 | $10,558 |
| Calcium Acetate | 27 | $4,384 |
| Midodrine Hcl | 29 | $2,244 |
| Cinacalcet Hcl | 19 | $1,950 |
| Bumetanide | 11 | $1,023 |
| Pantoprazole Sodium | 31 | $838 |
| Furosemide | 71 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $25 | $69,12969 claims |
| Fresenius USA Marketing, Inc.Velphoro | $78 | $41,67216 claims |
| AstraZenecaFarxiga | $194 | $32,59022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Escondido
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.